ADAP
Price
$0.18
Change
+$0.02 (+12.50%)
Updated
Oct 15, 11:16 AM (EDT)
Capitalization
42.73M
20 days until earnings call
Intraday Buy/Sell Signals
ORMP
Price
$2.30
Change
-$0.06 (-2.54%)
Updated
Oct 15, 11:11 AM (EDT)
Capitalization
96.77M
29 days until earnings call
Intraday Buy/Sell Signals
Interact to see
Advertisement

ADAP vs ORMP

Header iconADAP vs ORMP Comparison
Open Charts ADAP vs ORMPBanner chart's image
Adaptimmune Therapeutics
Price$0.18
Change+$0.02 (+12.50%)
Volume$144.9K
Capitalization42.73M
Oramed Pharmaceuticals
Price$2.30
Change-$0.06 (-2.54%)
Volume$3.28K
Capitalization96.77M
ADAP vs ORMP Comparison Chart in %
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
ADAP vs. ORMP commentary
Oct 16, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ADAP is a Hold and ORMP is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Oct 16, 2025
Stock price -- (ADAP: $0.16 vs. ORMP: $2.36)
Brand notoriety: ADAP and ORMP are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ADAP: 42% vs. ORMP: 149%
Market capitalization -- ADAP: $42.73M vs. ORMP: $96.77M
ADAP [@Biotechnology] is valued at $42.73M. ORMP’s [@Biotechnology] market capitalization is $96.77M. The market cap for tickers in the [@Biotechnology] industry ranges from $105.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.02B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ADAP’s FA Score shows that 0 FA rating(s) are green whileORMP’s FA Score has 0 green FA rating(s).

  • ADAP’s FA Score: 0 green, 5 red.
  • ORMP’s FA Score: 0 green, 5 red.
According to our system of comparison, ADAP is a better buy in the long-term than ORMP.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ADAP’s TA Score shows that 6 TA indicator(s) are bullish while ORMP’s TA Score has 4 bullish TA indicator(s).

  • ADAP’s TA Score: 6 bullish, 3 bearish.
  • ORMP’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, ADAP is a better buy in the short-term than ORMP.

Price Growth

ADAP (@Biotechnology) experienced а +16.31% price change this week, while ORMP (@Biotechnology) price change was -4.84% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.44%. For the same industry, the average monthly price growth was +17.42%, and the average quarterly price growth was +81.94%.

Reported Earning Dates

ADAP is expected to report earnings on Nov 05, 2025.

ORMP is expected to report earnings on Nov 14, 2025.

Industries' Descriptions

@Biotechnology (+0.44% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
ORMP($96.8M) has a higher market cap than ADAP($42.7M). ORMP YTD gains are higher at: -2.479 vs. ADAP (-70.076). ORMP has higher annual earnings (EBITDA): -22.07M vs. ADAP (-149.75M). ORMP has more cash in the bank: 97.9M vs. ADAP (26.1M). ORMP has less debt than ADAP: ORMP (912K) vs ADAP (48.7M). ADAP has higher revenues than ORMP: ADAP (65.1M) vs ORMP (2M).
ADAPORMPADAP / ORMP
Capitalization42.7M96.8M44%
EBITDA-149.75M-22.07M678%
Gain YTD-70.076-2.4792,826%
P/E RatioN/A20.91-
Revenue65.1M2M3,255%
Total Cash26.1M97.9M27%
Total Debt48.7M912K5,340%
FUNDAMENTALS RATINGS
ADAP vs ORMP: Fundamental Ratings
ADAP
ORMP
OUTLOOK RATING
1..100
2158
VALUATION
overvalued / fair valued / undervalued
1..100
39
Fair valued
67
Overvalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
10095
PRICE GROWTH RATING
1..100
3651
P/E GROWTH RATING
1..100
10045
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

ADAP's Valuation (39) in the Biotechnology industry is in the same range as ORMP (67) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ADAP's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ORMP (100) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's SMR Rating (95) in the Pharmaceuticals Other industry is in the same range as ADAP (100) in the Biotechnology industry. This means that ORMP’s stock grew similarly to ADAP’s over the last 12 months.

ADAP's Price Growth Rating (36) in the Biotechnology industry is in the same range as ORMP (51) in the Pharmaceuticals Other industry. This means that ADAP’s stock grew similarly to ORMP’s over the last 12 months.

ORMP's P/E Growth Rating (45) in the Pharmaceuticals Other industry is somewhat better than the same rating for ADAP (100) in the Biotechnology industry. This means that ORMP’s stock grew somewhat faster than ADAP’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
ADAPORMP
RSI
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 3 days ago
81%
Bullish Trend 3 days ago
72%
Momentum
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
79%
MACD
ODDS (%)
N/A
Bearish Trend 3 days ago
78%
TrendWeek
ODDS (%)
Bullish Trend 3 days ago
81%
Bearish Trend 3 days ago
80%
TrendMonth
ODDS (%)
Bullish Trend 3 days ago
85%
Bearish Trend 3 days ago
82%
Advances
ODDS (%)
Bullish Trend 8 days ago
78%
Bullish Trend 10 days ago
83%
Declines
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 8 days ago
81%
BollingerBands
ODDS (%)
Bearish Trend 3 days ago
90%
Bearish Trend 3 days ago
81%
Aroon
ODDS (%)
Bullish Trend 3 days ago
90%
Bullish Trend 3 days ago
84%
View a ticker or compare two or three
Interact to see
Advertisement
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ORMP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
XTPT1.550.25
+19.23%
Xtra Energy Corp.
JHIUF21.490.10
+0.49%
James Hardie Industries plc
CLZNF9.34N/A
N/A
Clariant AG
SHVLF0.44-0.01
-1.37%
Starcore International Mines, Ltd.
INTO0.11-0.14
-56.00%
Initio, Inc.

ADAP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with AKBA. These tickers have moved in lockstep 41% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then AKBA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-10.49%
AKBA - ADAP
41%
Loosely correlated
+0.36%
ORMP - ADAP
36%
Loosely correlated
-2.07%
ETNB - ADAP
34%
Loosely correlated
N/A
CSLLY - ADAP
32%
Poorly correlated
+1.01%
AXON - ADAP
31%
Poorly correlated
-0.75%
More

ORMP and

Correlation & Price change

A.I.dvisor indicates that over the last year, ORMP has been loosely correlated with BTAI. These tickers have moved in lockstep 44% of the time. This A.I.-generated data suggests there is some statistical probability that if ORMP jumps, then BTAI could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ORMP
1D Price
Change %
ORMP100%
-2.07%
BTAI - ORMP
44%
Loosely correlated
+0.77%
INO - ORMP
44%
Loosely correlated
-1.21%
MBIO - ORMP
44%
Loosely correlated
+1.23%
ZNTL - ORMP
43%
Loosely correlated
-4.94%
RVMD - ORMP
42%
Loosely correlated
-2.56%
More